Drugs / A2B530
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05736731 | Apr 2023 → Dec 2026 expected | colorectal adenocarcinoma, malignant pancreatic neoplasm, non-small cell squamous lung carcinoma | A2 Biotherapeutics Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-09 | A2 Biotherapeutics Inc. | Results A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer a2bio.com ↗
A2 Bio also shared posters highlighting early safety and biomarker data from the ongoing EVEREST-1 clinical study |
| 2024-03-04 | A2 Biotherapeutics Inc. | Regulatory A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer a2bio.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-09 | A2 Biotherapeutics Inc. | A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer a2bio.com ↗ |
| 2024-03-04 | A2 Biotherapeutics Inc. | A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer a2bio.com ↗ |
| 2023-05-30 | A2 Biotherapeutics Inc. | A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers a2bio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2B530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05736731 ↗ |
| Action | Deplete | “A2 Bio hypothesizes that A2B530 Tmod CAR T-cell therapy will enable the killing of tumor target cells” NCT05736731 ↗ |
| Modality | Cell therapy | “A2B530,an autologous logic-gated Tmod™ CAR T-cell product” NCT05736731 ↗ |
| Route | Intravenous | “followed by a single dose of A2B530 intravenously on day 0” NCT05736731 ↗ |